Fulcrum Therapeutics, Inc. Stock News

Fulcrum Therapeutics (NASDAQ:FULC) has earned an average recommendation of “Buy” from the six research firms that are currently covering the company, Marketbeat reports. One analyst has rated the

Fulcrum Therapeutics, Inc. (FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced it is on track for sub

FDA signs off on Emergency Use Authorization for Humanigen's (OTCQB:HGEN) lenzilumab for compassionate use for preventing and treating cytokine storm in severely ill COVID-19 patients.Investigator-ini

CAMBRIDGE, Mass., April 02, 2020 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defin

Fulcrum Therapeutics, Inc. (FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced complete results from

Gainers Contura Energy, Inc. (NYSE: CTRA) shares surged 64.7% to close at $4.89 on Friday. Contura is expected to release Q4 results on March 18. Exterran Corporation (NYSE: EXTN...

Here's a roundup of top developments in the biotech space over the last 24 hours.Scaling The Peaks (Biotech Stocks Hitting 52-week highs on March 4) * 89bio Inc (NASDAQ: ETNB) * Arcus Biosciences In

CAMBRIDGE, Mass., March 05, 2020 -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with.

Biotech stocks came under significant weakness along with the broader market in the week ended Feb. 28. Despite fears the COVID-19 epidemic will likely drag global growth, the viral outbreak proved ad

Fulcrum Therapeutics, Inc. (FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced the company’s support

Fulcrum Therapeutics, Inc. (FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that it has completed

CAMBRIDGE, Mass., Feb. 25, 2020 -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with.

CAMBRIDGE, Mass., Feb. 20, 2020 -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with.

CAMBRIDGE, Mass., Jan. 29, 2020 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically define

The following is a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs on Jan. 13.) Arvinas Inc (NASDAQ: ARVN ) Baxter Int